GlobeNewsWire
29 Jun 2026, 11:40 UTC · 1h ago
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
29 Jun 2026, 11:40 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
The Phase 3 APPROACH study for HLP003 in Major Depressive Disorder is on track for topline data readout in Q4 2026. — Topline Phase 3 data is the most significant catalyst for a clinical-stage biotech, as it determines the path to commercialization.
+0.80Helus Pharma closed a $50 million underwritten offering to fund its balance sheet and the second Phase 3 trial, EMBRACE. — Securing capital reduces immediate liquidity risk and provides the runway necessary to execute late-stage trials.
+0.40Phase 2 signal detection results for HLP004 in Generalized Anxiety Disorder showed a ~10-point improvement in HAM-A scores over standard of care at 6 weeks. — Positive early data for a secondary pipeline asset increases the company's overall valuation and diversifies clinical risk.
+0.30Continue reading
6 related stories
Search tags
The Phase 3 APPROACH study has surpassed 88% enrollment. — High enrollment rates reduce the risk of trial delays and support the timeline for the Q4 2026 readout.
+0.20The company is progressing HLP005 toward candidate selection, with a viable candidate expected in the second half of 2027. — Early-stage pipeline progression provides long-term optionality but has minimal immediate impact on stock price.
+0.10Which stocks this story touches
The company successfully raised $50 million, reported positive Phase 2 and 3 clinical trial progress, and strengthened its leadership team.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
40m ago
